查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1534942

气喘：市场洞察、流行病学和预测（2024-2032）

Asthma Disease - Market Insight, Epidemiology, & Forecast (2024-2032F)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 155 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预期气喘市场在预测期内（2024-2032年）将成长约 5%。全球气喘盛行率的增加是由于环境因素、过敏原和生活方式的改变推动了气喘市场的成长。此外，针对气喘控制的新药和生物製剂的研究和开发取得进展。例如，2023年2月，Pulmatrix启动了PUR1900治疗过敏性支气管肺曲菌病（ABPA）和气喘的首例患者2b期研究。这项全球研究将在 16 週内评估安全性、耐受性和有效性，并将支持 Pulmatrix 和 Cipla 的合作伙伴关係，预计在2024年中期为气喘患者提供治疗。

根据已上市药物，市场包括TEZSPIRE、TRELEGY ELLIPTA、ARNUITY ELLIPTA、CINQAIR（reslizumab）、FASENRA（benralizumab）、DUPIXENT（dupilumab）、NUCALA（mepolizumab）、AIRSUPRA（albuterol、budesonide）、XOLAIR（omalizumab）。其中，TEZSPIRE将在2023年占据较大占有率。 TEZSPIRE 是作为治疗严重气喘的药物而销售的，它为儘管采用标准治疗但仍无法控制气喘的患者提供了一种新的有效的治疗选择，成为气喘市场的主要驱动力。其独特的作用机制针对并抑制胸腺基质淋巴细胞生成素（TSLP），这是气喘发炎的关键驱动因素，对各种类型的严重气喘具有广泛的疗效。 TEZSPIRE 的开发满足了治疗需求，有助于改善患者状况并减少病情加重的次数。该疗法不仅将扩大治疗方法的范围，还将透过增加医生对新医疗产品的使用以及增加对呼吸系统疾病创新生物製剂的开发投资来推动市场的发展。

为了更了解气喘疾病的市场采用情况，根据 7MM 在美国、德国、英国、法国、义大利、西班牙和日本等国家的市场情况进行了分析。到2023年，美国将占据压倒性的市场占有率。由于气喘盛行率高且医疗负担高，美国气喘市场规模相当大。例如，美国成年人气喘盛行率从2001年的6.9%上升到2021年的8.0%。越来越多的人意识到并诊断出气喘以及治疗方案的改进是推动市场扩张的因素。新型治疗剂的存在，包括与普通吸入器和片剂合併使用的生物製剂，可以改善间歇性和严重气喘的控制。对减少空气污染和加强现有结构的医疗设施和技术创新的需求也将刺激市场，政府和公司对药品生产的大力投资也将刺激市场。

市场上营运的主要公司包括AstraZeneca, GSK plc, Cipla, Teva Pharmaceutical Industries Ltd., Sanofi, Avillion LLP, Novartis AG, CHIESI Farmaceutici S.p.A., Boehringer Ingelheim International GmbH, AB Science等。

目录

第1章 市场介绍

  • 市场定义
  • 主要目的
  • 利害关係人
  • 限制

第2章 研究方法或前提

  • 调查过程
  • 调查方法
  • 受访者简介

第3章 执行摘要

  • 行业概况
  • 依细分市场进行预测
    • 市场成长强度
  • 区域展望

第4章 市场动态

  • 促进因素
  • 机会
  • 抑制因素
  • 趋势

第5章 疾病背景与概论

  • 简介
  • 分类
  • 原因
  • 风险因素
  • 征兆和症状
    • 早期征兆和症状
    • 症状的进展
  • 诊断
    • 身体检查
    • 肺功能测试

第6章 治疗

  • 第一线治疗：吸入性皮质类固醇（ICS）
  • 支气管热成形术
  • 抗发炎
  • 伴随药物
  • 抗胆碱能药物
  • 生物製品
  • 抗生素
  • 其他
  • 新兴疗法
    • 免疫治疗
    • 其他

第7章 病人旅程

第8章 气喘指引

  • NICE 气喘管理建议
  • 英国气喘管理指南
  • 严重气喘定义、评估和治疗的国际 ERS/ATS 指南
  • 其他气喘指南

第9章 流行病学与病患人数，2022-2032年

  • 假设和理由
  • 7MM气喘流行病学
    • 7MM中气喘患者总数
    • 病例取决于气喘的严重程度
    • 严重气喘类型的病例
    • 依年龄划分的气喘患者人数（7MM）

第10章 气喘流行病学：依国家分类

  • 美国
    • 7MM中气喘患者总数
    • 病例取决于气喘的严重程度
    • 严重气喘类型的病例
    • 依年龄划分的气喘患者人数（7MM）
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 日本

第11章 气喘市场洞察、上市药物

  • TEZSPIRE（tezepelumab-ekko）：Amgen/AstraZeneca
    • 药物简介
    • 监理结果
    • 其他开发活动
    • 临床开发
    • 安全性和有效性
  • TRELEGY ELLIPTA (fluticasone furoate/umeclidinium/vilanterol)：GlaxoSmithKline
  • ARNUITY ELLIPTA (fluticasone furoate inhalation powder)：GlaxoSmithKline
  • CINQAIR (reslizumab)：Teva Pharmaceutical
  • FASENRA (benralizumab)：AstraZeneca
  • DUPIXENT (dupilumab)：Sanofi and Regeneron Pharmaceutical
  • NUCALA (mepolizumab)：GlaxoSmithKline (GSK)
  • AIRSUPRA (albuterol and budesonide)：AstraZeneca/Avillion
  • XOLAIR (omalizumab)：Novartis

第12章 气喘市场洞察、新药

  • GSK3511294 (Depemokimab)：GlaxoSmithKline
    • 药物简介
    • 临床开发
    • 安全性和有效性
  • Givinostat：Italfarmaco
  • Masitinib (AB07105)：AB Science
  • PT010：AstraZeneca
  • Dexpramipexole Dihydrochloride：Areteia Therapeutics
  • PBF-680：Palobiofarma SL/Pivotal S.L.
  • ARS 1：ARS Pharmaceuticals, Inc.
  • MEDI3506 (tozorakimab)：AstraZeneca
  • AZD1402 (PRS-060)：Pieris Pharma/AstraZeneca
  • Atuliflapon (AZD5718)：AstraZeneca
  • Amlitelimab：Sanofi

第13章 气喘市场：7MM 分析

  • 主要发现
  • 2022-2032年气喘总市场规模 7MM
  • 依已上市药物划分的气喘市场规模为 7MM
  • 以新药划分的气喘市场规模为 7MM
  • 2022-2032年美国市场规模
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 日本

第14章 未满足的需求

第15章 竞争态势

  • 主要竞争对手 - 已上市药品
  • 主要竞争对手 - III 期药品
  • 主要竞争对手 - II 期药品

第16章 公司简介

  • AstraZeneca
  • GSK plc
  • Cipla
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Avillion LLP
  • Novartis AG
  • CHIESI Farmaceutici S.p.A.
  • Boehringer Ingelheim International GmbH
  • AB Science

第17章 首字母缩写与先决条件

第18章 附录

简介目录
Product Code: UMHE212941

The asthma market refers to the market for products that are used to address this condition through the creation, manufacturing, and sale of drugs, devices, and therapies that help control and treat asthma, a long-term illness that results in inflammation of airways and constriction of the bronchi. There is a growing focus on respiratory diseases and the development of new treatments wherein the growth of the market is attributed to the increasing incidences of asthma, the growing awareness among people about respiratory wellness, and the emerging options in the form of new inhalers and biologics. Also, there are more favorable governmental policies and higher consumer demand for individualized treatment, which complements conceptions of therapy adherence and results in better asthma management market trends.

The asthma market is expected to grow around ~5% during the forecast period (2024-2032). The Increasing incidence of asthma globally is due to environmental factors, allergens, and lifestyle changes that drive the growth of the asthma market. Also, ongoing research and development of new drugs and biologics targeting asthma control. For instance, in February 2023, Pulmatrix initiated a Phase 2b trial, dosing the first patient with PUR1900 for Allergic Bronchopulmonary Aspergillosis (ABPA) and asthma. The global study will assess safety, tolerability, and efficacy over 16 weeks, supporting Pulmatrix's collaboration with Cipla to bring therapy to patients with asthma, with proof-of-concept data expected by mid-2024.

Based on the marketed therapies, the market has been divided into TEZSPIRE, TRELEGY ELLIPTA, ARNUITY ELLIPTA, CINQAIR (reslizumab), FASENRA, (benralizumab), DUPIXENT (dupilumab), NUCALA (mepolizumab), AIRSUPRA (albuterol and budesonide), and XOLAIR (omalizumab). Among them, the TEZSPIRE held a significant market share in 2023. TEZSPIRE, a marketed therapy for severe asthma, is significantly driving the asthma market by offering a novel and effective treatment option for patients with uncontrolled asthma despite standard therapies. Its unique mechanism of action targets and inhibits thymic stromal lymphopoietin (TSLP), a key driver of asthma inflammation, providing broader efficacy across various types of severe asthma. The development of TEZSPIRE responds to a therapeutic need and contributes to the enhancement of the patient's status and the decrease in the number of exacerbations. Besides broadening the therapeutic approach, this therapy contributes to market development by increasing the use of new medical products by physicians and increasing investment in the development of innovative biologicals for respiratory diseases.

For a better understanding of the market adoption of asthma disease, the market is analyzed based on its 7MM presence in countries such as The U.S., Germany, the UK, France, Italy, Spain, and Japan. The U.S. held a dominant share of the market in 2023. The U.S. market for asthma diseases is substantial, driven by the high prevalence and significant healthcare burden of the disease. For instance, the current asthma prevalence among adults in the U.S. increased from 6.9% in 2001 to 8.0% in 2021. Larger populations aware and diagnosed, coupled with improved treatment choices, are the factors that help in the expansion of the market. The presence of novel treatment, including biologics, in combination with the common inhalers and tablets improves the control of both intermittent and severe asthma. The demand for healthcare facilities and innovations to decrease air pollution and enhance existing structures along with strong investment in pharmaceutical production by governments and companies also stimulate the market.

Some of the major players operating in the market include AstraZeneca, GSK plc, Cipla, Teva Pharmaceutical Industries Ltd., Sanofi, Avillion LLP, Novartis AG, CHIESI Farmaceutici S.p.A., Boehringer Ingelheim International GmbH, and AB Science.

TABLE OF CONTENTS

1.MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Asthma Market
  • 2.2. Research Methodology of the Asthma Market
  • 2.3. Respondent Profile

3.EXECUTIVE SUMMARY

  • 3.1. Industry Synopsis
  • 3.2. Segmental Outlook
    • 3.2.1. Market Growth Intensity
  • 3.3. Regional Outlook

4.MARKET DYNAMICS

  • 4.1. Drivers
  • 4.2. Opportunity
  • 4.3. Restraints
  • 4.4. Trends

5.DISEASE BACKGROUND AND OVERVIEW

  • 5.1. Introduction
  • 5.2. Classification
  • 5.3. Causes
  • 5.4. Risk Factors
  • 5.5. Signs and Symptoms
    • 5.5.1. Early Signs and Symptoms
    • 5.5.2. Progressed Symptoms
  • 5.6. Diagnosis
    • 5.6.1. Physical exam
    • 5.6.2. Lung Function Tests

6.TREATMENT

  • 6.1. First Line Treatment - Inhaled corticosteroids (ICS)
  • 6.2. Bronchial Thermoplasty
  • 6.3. Anti-inflammatory
  • 6.4. Combination Medicines
  • 6.5. Anticholinergics
  • 6.6. Biologics
  • 6.7. Antibiotics
  • 6.8. Others
  • 6.9. Emerging Therapies
    • 6.9.1. Immunotherapy
    • 6.9.2. Others

7.PATIENT JOURNEY

8.GUIDELINES ON ASTHMA

  • 8.1. NICE Recommendations for Asthma Management
  • 8.2. British Guidelines on the Management of Asthma
  • 8.3. International ERS/ATS Guidelines on the Definition, Evaluation, and Treatment of Severe Asthma
  • 8.4. Other Guidelines for Asthma

9.EPIDEMIOLOGY & PATIENT POPULATION, 2022-2032F

  • 9.1. Assumptions and Rationale
  • 9.2. Epidemiology of Asthma in 7MM
    • 9.2.1. Total Prevalent Population of Asthma in the 7MM
    • 9.2.2. Severity-specific cases of Asthma
    • 9.2.3. Type-specific cases of Severe Asthma
    • 9.2.4. Age-specific Prevalent Population of Asthma in the 7MM

10.EPIDEMIOLOGY OF ASTHMA BY COUNTRY

  • 10.1. The United States
    • 10.1.1. Total Prevalent Population of Asthma in the 7MM
    • 10.1.2. Severity-specific cases of Asthma
    • 10.1.3. Type-specific cases of Severe Asthma
    • 10.1.4. Age-specific Prevalent Population of Asthma in the 7MM
  • 10.2. Germany
  • 10.3. UK
  • 10.4. France
  • 10.5. Italy
  • 10.6. Spain
  • 10.7. Japan

11.ASTHMA MARKET INSIGHTS, MARKETED THERAPIES

  • 11.1. TEZSPIRE (tezepelumab-ekko): Amgen/AstraZeneca
    • 11.1.1. Drug Profile
    • 11.1.2. Regulatory Achievements
    • 11.1.3. Other Development Activities
    • 11.1.4. Clinical Development
    • 11.1.5. Safety and Efficacy
  • 11.2. TRELEGY ELLIPTA (fluticasone furoate/umeclidinium/vilanterol): GlaxoSmithKline
  • 11.3. ARNUITY ELLIPTA (fluticasone furoate inhalation powder): GlaxoSmithKline
  • 11.4. CINQAIR (reslizumab): Teva Pharmaceutical
  • 11.5. FASENRA (benralizumab): AstraZeneca
  • 11.6. DUPIXENT (dupilumab): Sanofi and Regeneron Pharmaceutical
  • 11.7. NUCALA (mepolizumab): GlaxoSmithKline (GSK)
  • 11.8. AIRSUPRA (albuterol and budesonide): AstraZeneca/Avillion
  • 11.9. XOLAIR (omalizumab): Novartis

Complete List in the report

12.ASTHMA MARKET INSIGHTS, EMERGING THERAPIES

  • 12.1. GSK3511294 (Depemokimab): GlaxoSmithKline
    • 12.1.1. Drug Profile
    • 12.1.2. Clinical Development
    • 12.1.3. Safety and Efficacy
  • 12.2. Givinostat: Italfarmaco
  • 12.3. Masitinib (AB07105): AB Science
  • 12.4. PT010: AstraZeneca
  • 12.5. Dexpramipexole Dihydrochloride: Areteia Therapeutics
  • 12.6. PBF-680: Palobiofarma SL/Pivotal S.L.
  • 12.7. ARS 1: ARS Pharmaceuticals, Inc.
  • 12.8. MEDI3506 (tozorakimab): AstraZeneca
  • 12.9. AZD1402 (PRS-060): Pieris Pharma/AstraZeneca
  • 12.10. Atuliflapon (AZD5718): AstraZeneca
  • 12.11. Amlitelimab: Sanofi

Complete List in the report

13.ASTHMA MARKET: 7MM ANALYSIS

  • 13.1. Key Findings
  • 13.2. Total Market Size of Asthma in the 7MM, 2022-2032F
  • 13.3. Market Size of Asthma by Marketed Therapies in the 7MM
  • 13.4. Market Size of Asthma by Emerging Therapies in the 7MM
  • 13.5. United States Market Size, 2022-2032F
    • 13.5.1. Total Market Size of Asthma in the United States
    • 13.5.2. Market Size of Asthma by Marketed Therapies in the United States
    • 13.5.3. Market Size of Asthma by Emerging Therapies in the United States
  • 13.6. Germany
  • 13.7. UK
  • 13.8. France
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. Japan

14.UNMET NEEDS

15.COMPETITIVE LANDSCAPE

  • 15.1. Key Competitors - Marketed Therapies
  • 15.2. Key Competitors - Phase III Drugs
  • 15.3. Key Competitors - Phase II Drugs

16.COMPANY PROFILES

  • 16.1. AstraZeneca
    • 16.1.1. Company Overview
    • 16.1.2. Key Financials
    • 16.1.3. SWOT Analysis
    • 16.1.4. Product Portfolio
    • 16.1.5. Recent Developments
  • 16.2. GSK plc
  • 16.3. Cipla
  • 16.4. Teva Pharmaceutical Industries Ltd.
  • 16.5. Sanofi
  • 16.6. Avillion LLP
  • 16.7. Novartis AG
  • 16.8. CHIESI Farmaceutici S.p.A.
  • 16.9. Boehringer Ingelheim International GmbH
  • 16.10. AB Science

17.ACRONYMS & ASSUMPTION

18.ANNEXURE